Protalex, Inc. (PRTX) Reports Positive Interim Review of Phase 1b Trial of PRTX-100 in Rheumatoid Arthritis by Independent Data Safety Monitoring Committee
5/22/2013 10:06:51 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its independent Data Safety Monitoring Committee, the Company is continuing enrollment and increasing the dose for subjects in its multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA). The dose of PRTX-100 for subjects in the current treatment group (12.0 micrograms/kg) is eight times that of the initial starting dosage (1.5 micrograms/kg).
Help employers find you! Check out all the jobs and post your resume.
comments powered by